These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 35614939)

  • 21. Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis.
    Namisaki T; Kaji K; Shimozato N; Kaya D; Ozutsumi T; Tsuji Y; Fujinaga Y; Kitagawa K; Furukawa M; Sato S; Sawada Y; Nishimura N; Takaya H; Okura Y; Seki K; Kawaratani H; Moriya K; Noguchi R; Asada K; Akahane T; Mitoro A; Yoshiji H
    Indian J Gastroenterol; 2022 Apr; 41(2):169-180. PubMed ID: 35279807
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Farnesoid X receptor (FXR) agonists induce hepatocellular apoptosis and impair hepatic functions via FXR/SHP pathway.
    Zhang T; Feng S; Li J; Wu Z; Deng Q; Yang W; Li J; Pan G
    Arch Toxicol; 2022 Jun; 96(6):1829-1843. PubMed ID: 35267068
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulation of Intestinal UDP-Glucuronosyltransferase 1A1 by the Farnesoid X Receptor Agonist Obeticholic Acid Is Controlled by Constitutive Androstane Receptor through Intestinal Maturation.
    Weber AA; Mennillo E; Yang X; van der Schoor LWE; Jonker JW; Chen S; Tukey RH
    Drug Metab Dispos; 2021 Jan; 49(1):12-19. PubMed ID: 33154041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of Farnesoid X Receptor Activation on Arachidonic Acid Metabolism, NF-kB Signaling, and Hepatic Inflammation.
    Gai Z; Visentin M; Gui T; Zhao L; Thasler WE; Häusler S; Hartling I; Cremonesi A; Hiller C; Kullak-Ublick GA
    Mol Pharmacol; 2018 Aug; 94(2):802-811. PubMed ID: 29743187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease.
    Abenavoli L; Falalyeyeva T; Boccuto L; Tsyryuk O; Kobyliak N
    Pharmaceuticals (Basel); 2018 Oct; 11(4):. PubMed ID: 30314377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Obeticholic acid differentially regulates hepatic injury and inflammation at different stages of D-galactosamine/lipopolysaccharide-evoked acute liver failure.
    Ding W; Fan YY; Zhang C; Fu L; Chen X; Xu DX
    Eur J Pharmacol; 2019 May; 850():150-157. PubMed ID: 30772394
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice.
    Jouihan H; Will S; Guionaud S; Boland ML; Oldham S; Ravn P; Celeste A; Trevaskis JL
    Mol Metab; 2017 Nov; 6(11):1360-1370. PubMed ID: 29107284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Obeticholic acid treatment ameliorates the cardiac dysfunction in NASH mice.
    Liu SY; Huang CC; Yang YY; Huang SF; Lee TY; Li TH; Hou MC; Lin HC
    PLoS One; 2022; 17(12):e0276717. PubMed ID: 36490253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiopulmonary protective effects of the selective FXR agonist obeticholic acid in the rat model of monocrotaline-induced pulmonary hypertension.
    Vignozzi L; Morelli A; Cellai I; Filippi S; Comeglio P; Sarchielli E; Maneschi E; Vannelli GB; Adorini L; Maggi M
    J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt B):277-292. PubMed ID: 27425465
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Obeticholic acid ameliorates dyslipidemia but not glucose tolerance in mouse model of gestational diabetes.
    McIlvride S; Nikolova V; Fan HM; McDonald JAK; Wahlström A; Bellafante E; Jansen E; Adorini L; Shapiro D; Jones P; Marchesi JR; Marschall HU; Williamson C
    Am J Physiol Endocrinol Metab; 2019 Aug; 317(2):E399-E410. PubMed ID: 31237448
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH.
    Carino A; Biagioli M; Marchianò S; Fiorucci C; Zampella A; Monti MC; Scarpelli P; Ricci P; Distrutti E; Fiorucci S
    Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Oct; 1864(10):1422-1437. PubMed ID: 31325638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FXR activation promotes intestinal cholesterol excretion and attenuates hyperlipidemia in SR-B1-deficient mice fed a high-fat and high-cholesterol diet.
    Singh AB; Dong B; Kraemer FB; Liu J
    Physiol Rep; 2020 Mar; 8(5):e14387. PubMed ID: 32170842
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis.
    Zhou J; Huang N; Guo Y; Cui S; Ge C; He Q; Pan X; Wang G; Wang H; Hao H
    Acta Pharm Sin B; 2019 May; 9(3):526-536. PubMed ID: 31193776
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emodin palliates high-fat diet-induced nonalcoholic fatty liver disease in mice via activating the farnesoid X receptor pathway.
    Shen C; Pan Z; Wu S; Zheng M; Zhong C; Xin X; Lan S; Zhu Z; Liu M; Wu H; Huang Q; Zhang J; Liu Z; Si Y; Tu H; Deng Z; Yu Y; Liu H; Zhong Y; Guo J; Cai J; Xian S
    J Ethnopharmacol; 2021 Oct; 279():114340. PubMed ID: 34171397
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination.
    Jung H; Chen J; Hu X; Sun H; Wu SY; Chiang CM; Kemper B; Chen LF; Kemper JK
    JCI Insight; 2020 Dec; 6(1):. PubMed ID: 33290278
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FXR agonists for MASH therapy: Lessons and perspectives from obeticholic acid.
    Wang K; Zhang Y; Wang G; Hao H; Wang H
    Med Res Rev; 2024 Mar; 44(2):568-586. PubMed ID: 37899676
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intestinal farnesoid X receptor signaling controls hepatic fatty acid oxidation.
    Lu D; Liu Y; Luo Y; Zhao J; Feng C; Xue L; Xu J; Wang Q; Yan T; Xiao P; Krausz KW; Gonzalez FJ; Xie C
    Biochim Biophys Acta Mol Cell Biol Lipids; 2022 Feb; 1867(2):159089. PubMed ID: 34856412
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasis.
    Carino A; Biagioli M; Marchianò S; Fiorucci C; Bordoni M; Roselli R; Di Giorgio C; Baldoni M; Ricci P; Monti MC; Morretta E; Zampella A; Distrutti E; Fiorucci S
    Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Sep; 1865(9):158733. PubMed ID: 32371093
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Co-administration of obeticholic acid and simvastatin protects against high-fat diet-induced non-alcoholic steatohepatitis in mice.
    Li WC; Zhao SX; Ren WG; Zhang YG; Wang RQ; Kong LB; Zhang QS; Nan YM
    Exp Ther Med; 2021 Aug; 22(2):830. PubMed ID: 34149876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of Nonalcoholic Steatohepatitis by Obeticholic Acid: Current Status.
    Roy PP; Mahtab MA; Rahim MA; Yesmin SS; Islam SB; Akbar SMF
    Euroasian J Hepatogastroenterol; 2022 Jul; 12(Suppl 1):S46-S50. PubMed ID: 36466097
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.